Renaissance Capital logo

Roivant Sciences (Montes Archimedes Acquisition) Priced, Nasdaq: ROIV

Blank check company formed by Patient Square Capital targeting the healthcare industry (completed 10/1/2021).

Industry: SPAC

First Day Return: -1.6%

Industry: SPAC

We are a newly incorporated blank check company. We will seek to capitalize on the more than 50 years of combined investing experience of our Founders, James C. Momtazee and Maria C. Walker. We believe our Founders' distinctive and complementary backgrounds can have a transformative impact on a target business. Although we may pursue targets in any business industry or sector, we intend to focus our investment efforts broadly across the entire health care industry, which encompasses among other things technology-enabled services, biopharmaceuticals, pharmaceutical value chain, medical devices, diagnostics, providers, digital health and consumer health. Investment opportunities will be sourced through the Founders' proprietary and differentiated network built over decades of investing in and growing health care businesses. The company will employ a disciplined and highly selective investment process that focuses on accessing differentiated opportunities through deep relationships with executives, advisors, and intermediaries to enhance the growth potential and value of a target business and provide opportunities for an attractive return to our shareholders.
more less
IPO Data
IPO File Date 09/15/2020
Offer Price $10.00
Price Range $10.00 - $10.00
Offer Shares (mm) 40.0
Deal Size ($mm) $400
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 10/06/2020
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $400
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters Menlo Park, CA, United States
Founded 2020
Employees at IPO 3
Website patientsquarecapital.com

Roivant Sciences (Montes Archimedes Acquisition) (ROIV) Performance